Venture Capital Access Online | Venture Capital News
Summary
and Patient-focused Technologies Financing to support accelerated deployment of the VieCure platform in cancer centers nationwide and globally, along with expanded partnerships with life sciences, molecular labs, payors, and oncology drug distribution companies DENVER, April 20, 2021-- VieCure, Inc. today announced the closing of its $25 million Series A growth equity investment, led by Northpond Ventures. VieCure is contracted with cancer centers and health systems in the United States, Bahamas, and Antigua, and has forged meaningful strategic alliances with global pharmaceutical, molecular diagnostic, and laboratory companies. This includes codified clinical and payor content, the smart EMR in oncology, the artificial intelligence inference engine, a tethered patient mobile app, an integrated teleoncology solution, and the most robust analytics functionality that facilitates immediate access to meaningful and curated datasets. The precision oncology paradigm shift is underway and the amount of data that clinicians are being expected to digest, consider, and action is often beyond the human condition. VieCure is contracted with cancer centers in the United States, Bahamas, and Antigua and has forged meaningful strategic alliances with global pharmaceutical, molecular diagnostic, and laboratory companies.